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Human brucellosis is a neglected zoonotic tropical disease, caused 
by facultative intracellular Gram-negative Brucella bacteria that are 
transmitted directly or indirectly from animals to people.[1] Five 
species, i.e. B. abortus, B. suis, B. melitensis, B. canis and B. ovis, have 
domestic animals (cattle, pigs, goats, dogs and sheep) as preferred 
hosts. Five Brucella species have been found in wildlife and sea 
mammals, with a further four atypical strains isolated from baboons, 
rodents, frogs and humans.[2] The incubation period for brucellosis in 
humans is reported to range from 1 to 5 weeks, with the disease being 
categorised into asymptomatic or symptomatic, with the latter noted to 
have either an acute or an insidious onset.[3,4] The symptomatic stage 
of the disease has been further classified according to the duration and 
severity of the symptoms as acute (lasting up to 8 weeks), subacute 
(lasting 8 weeks - 1 year) or chronic (lasting >1 year).[3,5] Brucellosis 
is also described as either uncomplicated or focal, where focal implies 
localisation of the bacterium in an organ system, resulting in symptoms 
related to that system.[6]
Symptomatic acute and subacute disease are typified by intermittent 
febrile illness that persists for 1 - 5 weeks, followed by a 2-day - 
2-week remission period, when symptoms are either reduced or 
absent,[5] resulting in the ‘undulant fever’ of brucellosis. Fever may 
be accompanied by malaise, anorexia, extreme physical weakness 
or emotional exhaustion. Clinical findings during these stages are 
usually fever, hepatomegaly and/or splenomegaly.[3] If the disease is not 
detected or treated correctly, it may persist for weeks or months and 
progress to the chronic form.[7]
Chronic brucellosis refers to symptomatic disease that has persisted 
for >1 year, and is usually associated with focal infection that can 
affect any organ system, revealing its multisystem nature.[8-10] The 
most common clinical signs, although nonspecific, include relapsing 
fevers, chills, sweating, joint pain, depression and ongoing recurrent 
infection.[4] Frequently reported focal infection include sacroiliitis, 
orchitis and epididymitis, while neurobrucellosis and endocarditis 
occur less often, but may result in death.[11]
‘Asymptomatic’ or ‘subclinical form of the disease’ is the 
terminology used to describe patients who are serologically positive 
for brucellosis, but have no clinical symptoms. This situation 
commonly occurs in veterinarians, abattoir workers, farmers or 
persons in endemic areas.[12]
Human brucellosis is a global health problem, with at least 
500 000 cases reported annually worldwide,[3] and with prevalence 
rates >10/100 000 population in some countries.[9] Brucellosis not 
only affects low- and middle-income countries, impacting poorer and 
more marginalised people,[13-16] but shows an evolving epidemiology 
with re-emerging endemic foci in countries where the disease is 
controlled in livestock.[17] Little is known about brucellosis in humans 
in Africa.[17] Country data on human brucellosis in sub-Saharan 
Africa are sparse and the true burden of the disease in this region is 
unknown.[17-19]
In South Africa (SA), bovine brucellosis is a controlled animal 
disease.[20,21] Human brucellosis is a notifiable medical condition, but 
there is currently no surveillance programme for this condition in 
SA.[21] Two cases of brucellosis in humans were reported in 2016 – 
1 from Western Cape[22] and 1 from Mpumalanga provinces.[21] This 
followed a published report of B. abortus infective endocarditis of a 
prosthetic valve in a patient from KwaZulu-Natal Province.[23] The 
article cites a 1962 paper by Schrire,[24] which reports the national 
incidence of human brucellosis to be <0.2/100 000 population. The 
paucity of reported cases of brucellosis since Schrire’s article is used 
to support the conclusion that the incidence of human brucellosis in 
SA is low, which could be indicative of effective vaccination against 
brucellosis in livestock.[23]
More recent literature emphasises the problem of under-diagnosis 
and under-reporting of human brucellosis in SA, highlighting 
medical practitioners’ unawareness of the disease.[22] Furthermore, 
Frean et al.[21] draw attention to the reprioritisation of B. abortus 
as a public health risk in SA and the measures being taken by 
government veterinary services to reduce this risk. In such papers, 
strong recommendation is made for clinician awareness, involvement 
and vigilance.
This article aims to increase practitioner awareness of brucellosis 
by presenting evidence of the historical importance of the disease in 
SA from the published literature. Clinical findings are reviewed in 
the context of the most pertinent challenges that clinicians face in the 
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detection, treatment and management of brucellosis in the current 
SA context.
History of human brucellosis in South 
Africa
In southern Africa, the first human case of brucellosis was reported 
in 1924; it was caused by B. abortus.[25,26] Outbreaks of abortions in 
cattle herds, first detected in 1906, were confirmed to be the result 
of B. abortus infections in 1913. These occurred in the Johannesburg 
area of the then Transvaal province.[27] Recent paleopathological 
evidence suggests that Brucella may even have been present in this 
area for longer, and may have been the cause of disease in the late 
Pliocene hominin species Australopithecus africanus (Stw 431) in the 
Sterkfontein caves complex, ~2.4 - 2.8 million years ago.[28]
The history of prioritisation of human brucellosis in southern 
Africa dates back to 1919, when Malta fever (caused by B. melitensis) 
was included as a notifiable human disease in the Public Health Act 
of 1919. Human brucellosis, caused by B. abortus, was recognised 
as a public health risk in SA[26,29,30] 10 years after the discovery of 
the zoonotic nature of the bacterium.[31] This conclusion was based 
on substantial evidence of undulant fever cases in man attributed 
to Brucella spp. that did not share the morphological or culture 
conditions of B. melitensis and was not associated with direct or 
indirect contact with goats, but instead with direct or indirect 
contact with cattle.[26] Human cases of undulant fever, caused by 
B. abortus, were notified as Malta fever, and were detected and 
reported from all provinces of the Union of SA (except Natal) from 
1928 to 1980.[26,30,32-35]
In 1938, clusters of cases were identified in the Transvaal.[32] The 
endemic state in the north-eastern Transvaal and the then South 
West Africa, was highlighted in 1958,[36] and human brucellosis was 
reported to be a disease more common in SA than was generally 
believed. In 1959, brucellosis in humans was recognised as a problem, 
specifically in Krugersdorp, but also in the entire Transvaal.[37] The 
endemicity of this region was further supported by Schrire,[34] who 
identified the northern and eastern Transvaal, the Witwatersrand and 
Swaziland as areas representing 66.4% (n=77/116) of cases reported 
between 1956 and 1959. Furthermore, evidence of a risk to the public 
through the consumption of contaminated milk was identified on the 
Witwatersrand[38] and northern Highveld[39] regions of the Transvaal 
in 1948 and 1962, respectively.
The importance of brucellosis as a disease in humans seems to have 
diminished significantly by 1980. A publication by Mauff[35] reported 
7 cases of acute brucellosis within a 9-month period, 5 of which were 
associated with a new abattoir plant in Johannesburg – an unusual 
event. The last reported annual incidence rates from an analysis by 
the National Department of Health in 1977 and 1984, was 0.1/100 000 
and 0.3/100 000 population, respectively.[21]
However, after 1980, interest in Brucella continued ‒ research was 
done regarding its use as a biological weapon in SA.[40] In this covert 
government programme, B. melitensis and B. abortus are mentioned 
on the list of pathogens available for sale by Roodeplaat Research 
Laboratories. On the list, B. abortus is identified as ‘terminating 
pregnancy in cows’.[40] During this period, there was a paucity of 
published articles on human brucellosis.
Prevention of brucellosis caused by 
Brucella abortus
B. abortus, the cause of bovine brucellosis, is considered one of the 
major zoonotic species causing human brucellosis in SA.[21] B. abortus 
occurs in cattle and may also occur in horses, pigs, sheep, goats, 
Bactrian camels, dromedary camels, water buffalo and yaks,[41] as well 
as wildlife species, such as the African buffalo, hippopotamus, zebra, 
eland and impala.[42,43] 
Brucella-infected cattle are characterised by ≥1 of the following 
symptoms: abortion, retained placenta, stillbirths, poor weight gain, 
orchitis, epididymitis and hygromas.[27] In cattle, B. abortus causes 
abortions ‒ usually in the third trimester. Bacterial concentrations 
in the placenta and fetal tissues can be as high as 109 - 1010 CFU/g 
and are therefore the main source of transmission to humans or 
uninfected bovines through aerosolised or direct mucosal contact, 
where a minimum dose within the 103 - 104 CFU range is needed 
for infection.[44] Infection of the reproductive system does not always 
lead to abortion, but can persist in a herd without any overt clinical 
symptoms, except for the birth of weak or non-viable calves and a 
reduction in milk yield.[41,44]
Therefore, direct contact with infected reproductive material or 
uterine discharge or indirect contact through the ingestion of bacteria 
shed in the milk are the main routes of transmission of B. abortus to 
humans and to other cattle. Further sources of infection have been 
reported, i.e. a contaminated environment, especially if it is wet and 
muddy, or contact with equipment used for milking or artificial 
insemination.[27]
Global evidence of the zoonotic and economic importance of 
bovine brucellosis resulted in the emergence of national bovine 
brucellosis eradication schemes.[31,41,45] SA was among the countries 
that initiated such a scheme, supported by legislation and regulated 
by veterinary state services in response to the economic and zoonotic 
threat of the disease in cattle.[46-48] At the time, such schemes 
were being successfully implemented in developed countries, and 
relied on a well co-ordinated and managed veterinary services 
programme to reduce cattle and herd infection levels through 
vaccination and subsequent cattle test and slaughter programmes.[49-54] 
Since the inception of bovine brucellosis eradication schemes, the 
USA,[44] Sweden, Finland, Denmark, the UK (excluding Northern 
Ireland), Germany, Luxembourg, Belgium, the Netherlands, Austria, 
Switzerland, Norway, France,[17] Malta[55] and Australia[56] have 
achieved bovine brucellosis-free status.
Vaccination of cattle with weakened live vaccines against B. abortus 
is a critical component of bovine brucellosis eradication or control 
programmes.[57] Two weakened vaccines, S19 and RB51, have been 
registered for use in national bovine brucellosis eradication pro-
grammes.[42] While human infection with S19 can be treated with 
the recommended course of antibiotics, the attenuated live rough 
strain, RB51, is a rifampicin-resistant attenuated strain of the smooth 
B. abortus biovar 1 S2308 strain.[57,58] This strain has been shown to 
cause infection in occupationally exposed persons at an estimated rate 
of 2 unintentional needle-stick injuries for every 1 000 inocu lations 
performed,[59] and has resulted in several outbreaks affecting consum-
ers of milk in the USA.[60-62] Routine serological tests are unable to 
detect infection with RB51,[60,63] presenting a diagnostic challenge to 
clinicians suspecting brucellosis. 
In SA, control of bovine brucellosis began with compulsory 
vaccination of cattle with S19. Testing for bovine brucellosis for 
maintenance and export purposes has been conducted since 1913 at 
the Ondesterpoort laboratory in Pretoria, SA.[47] Further organisation 
of control activities began in 1978 with the introduction of the bovine 
brucellosis eradication scheme, which was first announced in 1968, 
but became effective after 1976.[64] This scheme, which was officially 
nationally ratified and promulgated in 1989, was aimed at preventing 
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and controlling brucellosis in cattle, which would in turn reduce 
brucellosis in humans and increase cattle herd productivity.
SA has since undergone a political shift from an apartheid 
government to a democratic government over the century spanning 
the initial discovery of B. melitensis and B. abortus.[31,65] The political 
shift resulted in the decentralisation of veterinary services in 1994. 
This led to implementation of the bovine brucellosis eradication 
programme in the mandate of the 9 provincial veterinary services[20] 
to ensure an extension of such services to the previously marginalised 
group of mixed-race cattle farmers. Currently, a revision of the 
bovine brucellosis eradication scheme of 1980 is proposed to 
change from voluntary testing to compulsory testing of all cattle in 
SA.[20,21] Vaccination of cattle herds and testing and slaughtering of 
infected cattle still form critical components of the strategy. Persons 
occupationally exposed to Brucella-infected cattle herds and those 
who routinely vaccinate, test or slaughter infected cattle, are therefore 
currently at risk of brucellosis.
Detection and diagnosis of brucellosis
Difficulty in detecting and diagnosing brucellosis is well described in 
the literature[2,66-70] and is a major constraint in the early and accurate 
detection of brucellosis worldwide.[2,66] Such difficulty is primarily 
due to the symptomatic phase of brucellosis being marked by 
nonspecific symptoms that are common to other infectious diseases, 
such as malaria, tuberculosis and the common flu.[66] Fever is not 
always associated with a detectable bacteraemia, which reduces the 
sensitivity of isolation and culture of bacteria from blood or tissue 
during the symptomatic phase,[2,66,71] thus limiting the use of available 
molecular techniques.
Serological tests are more affordable than molecular tests and 
have been successfully used in resource-constrained settings.[72,73] 
Clinicians have relied on available serological tests to support 
the diagnosis of brucellosis to initiate treatment.[19,72,73] To detect 
the progression of the disease or diagnose brucellosis, sequential 
serological tests conducted 1 - 2 weeks apart are recommended, as 
tests may be negative in the early stages of the disease.[2,66,68]
However, the abovementioned articles report that brucellosis 
patients who have been successfully treated or who have recovered 
without treatment[5] may remain seropositive for several months or 
years, making differentiation between patients with active disease 
and those with past disease – but presenting with brucellosis-like 
symptoms – difficult. To address this diagnostic complication, the 
literature recommends that the prevalence of brucellosis in healthy 
individuals should be measured to determine a reliable cut-off value 
for serological tests used by clinicians to diagnose the condition in 
endemic regions.[66]
SA clinicians experienced similar difficulties in detecting and 
diagnosing brucellosis. They reported that serological agglutination 
tests were not specific or sensitive enough to differentiate between 
B. melitensis, B. abortus and B. abortus intermediate type.[30] The 
low sensitivity of culture to confirm brucellosis was also a concern. 
This is illustrated in reports of patients who tested seropositive for 
brucellosis while presenting with subacute endocarditis, but who 
were culture negative for Brucella and culture positive Streptococcus 
viridans.[30]
The most reported challenge for clinicians at that time was 
interpreting serological test results and determining appropriate 
titre cut-offs to confirm a diagnosis of brucellosis in patients with 
fever of unknown origin, when malaria, typhoid, paratyphoid and 
tuberculosis were already ruled out.[30,32] Campbell and Greenfield,[30] 
in 1937, made use of live suspensions of B. melitensis and the 
Rhodesian strain of B. abortus as antigen for agglutination tests and 
used a minimum titre of 1:400 to diagnose brucellosis in patients 
with fever of unknown origin. They reported a 4.84% prevalence 
(n=32/661). The authors regarded a titre of 1:100 - 1:200 (9.36%) as 
probable cases or cases of brucellosis.[30] This titre was higher than 
that used in a seroprevalence survey conducted by Barnetson[32] from 
1936 to 1938 to determine the frequency of Brucella agglutinins in 
SA. In this study, 1 900 blood samples routinely submitted to the SA 
Institute for Medical Research to test for typhoid fever, were tested 
for antibodies to B. abortus and B. melitensis antigens ‒ a titre of 
1:50 being indicative of brucellosis. Using this titre, the incidence of 
brucellosis was reported as 2.5% (n=40/1577) for the country during 
this period.
The indirect Coombs test was employed over 3 years to determine 
the frequency of Brucella antibodies in 2 393 patients.[33] This 
test could detect non-agglutinating antibodies to Brucella and 
was therefore considered more sensitive to detect past or present 
infection. Patients who were tested were provisionally diagnosed 
with one of the following: arthritis, acute rheumatism, brucellosis, 
pyrexia of unknown origin, backache, pneumonitis, anaemia, 
adenitis, hepatosplenomegaly, hepatitis or tuberculosis – there was 
also a proportion for whom no diagnosis was provided. Twenty-one 
percent of these patients were seropositive to the indirect Coombs 
test compared with 5% of 300 randomly selected controls comprised 
of blood donors and antenatal patients.
An accepted explanation for brucellosis titres in healthy South 
Africans in the 1960s, was that they were exposed to the non-virulent 
Brucella antigen;[74] therefore, positive titres do not necessarily denote 
active infection. This led to a deprioritisation of the possibility of 
disease, especially among occupationally exposed persons, such as 
farmers, abattoir workers and veterinarians, who showed serological 
titre levels without clinical symptoms of disease.[35,74] In contrast, 
other literature showed that farmers and veterinarians who are 
frequently exposed to Brucella tend to display a hypersensitivity 
reaction that causes symptoms typical of acute brucellosis.[12,59] 
Furthermore, recent international studies suggest that the absence 
of clinical symptoms in the presence of a high serological titre may 
be indicative of patients who have the subclinical or latent form of 
the disease ‒ also known as the asymptomatic stage.[9] Moreover, 
evidence of exposure does not imply a consistent immunity, as 
immunity after infection lasts for ~2 years[5] and infection is known 
to be dose dependent.[75] The development of chronic and subclinical 
brucellosis, marked by the temporary absence of clinical symptoms, 
has also been noted in these occupational groups.[8,12,37,76]
In SA, currently, the most commonly used serological tests are the 
Coombs anti-Brucella test, the serum agglutination test (SAT), the 
rose Bengal test (RBT), complement fixation and the enzyme-linked 
immunosorbent assay (ELISA),[21] with the Coombs anti-Brucella 
test being regarded as the most specific to diagnose brucellosis. 
The RBT is affordable and sensitive to sera without blocking or 
non-agglutinating antibodies, which is typically the situation in 
non-chronic cases of a short evolution of disease,[72] and is therefore 
useful to detect acute cases of brucellosis. However, in endemic 
areas it is reported to have a low specificity[2] and a low sensitivity 
to detect chronic and complicated brucellosis patients.[2,77] The 
ELISA IgG has been reported to be a very sensitive serological test 
to detect antibodies of the IgG class, which are predominately found 
in the chronic phase of brucellosis, and is useful for detecting focal, 
complicated and chronic disease.[77] Cut-offs for best sensitivity and 
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specificity in endemic areas were determined to be 10.00 IU/mL[70] 
and 10.78 IU/mL, respectively.[78] However, the most sensitive and 
specific test to detect complicated and chronic brucellosis in an 
endemic area, is reported to be the BrucellaCapt test.[66,77,79] This 
serological test is regarded as more sensitive and specific than the 
RBT or ELISA IgG to detect chronic reinfections and persistent 
or relapsing cases of brucellosis.[66,69] This commercially available 
immune capture serological test[80] is based on the principles of the 
Coombs anti-Brucella test. It is cost-effective, rapid and reported to 
have a sensitivity and specificity of 99.2% and 96%, respectively, on 
samples determined positive by the Coombs test.[81] Furthermore, 
BrucellaCapt titres indicate the activity of infection, regardless of the 
stage of disease, decreasing slowly after relapse and more distinctly 
after treatment.[2] The test was, however, developed to diagnose 
brucellosis in non-endemic countries and needs an adjustment of the 
cut-off titre to detect cases if used in an endemic area.[78]
Clinical symptoms 
A multitude of symptoms affecting every body system, associated 
with a culture-positive or seropositive reaction to Brucella antigens, 
were reported by SA clinicians from 1935 onwards.[12,23,29,30,34,36,37,82] 
Fever and chills, pyrexia of long duration, continuous fever of 
6 weeks’ duration, fever of some months’ duration, low pyrexia, 
pyrexia of unknown origin and sweating have been associated with 
brucellosis.[29,30,33,83]
Lesions of the skin were described in veterinarians, cattle 
handlers who removed placentas, farmers and abattoir workers. 
They presented with erythematous granulomatous lesions or a skin 
rash lasting 4 - 8 hours,[29] progressing to a nodular rash lasting 
3 - 4 days, usually on the forearm, which sometimes caused gross 
thickening of the skin. This manifestation of brucellosis was termed 
erythematous brucellosis by Robinson[29] in 1935 and by Schrire in 
1962.[34] Signs of musculoskeletal involvement included arthralgia, 
pain in the joints, arthritis of the knee and ankle, described in 
a native Angolan mine worker and the wife of a medical doctor 
from Canada, whereas severe shoulder pain occurred in a farmer.[30,37] 
Sacroiliitis and backache were described in a mine worker and 
an 18-year-old son of a town dairy owner,[36,82] while a 65-year-
old woman presented with Brucella spondylitis accompanied by 
radiculitis, which was referred to as ‘sciatic neuritis’.[36,37,82] Other 
musculoskeletal symptoms described in brucellosis cases included 
peripheral arthritis, osteomyelitis, muscle wasting and palmar 
erythema.[29,36,37]
Hepatomegaly, cirrhosis of the liver, hepatosplenomegaly and 
hepatitis were also common findings in brucellosis patients. These 
conditions were sometimes associated with spider naevi on the 
chest.[29,33,36,37] Other respiratory symptoms included pleural effusions, 
pneumonias, pneumonitis and bronchopneumonia.[30] Hilar adeno-
pathy with a non-productive cough and focal pneumonitis was 
described in laboratory workers.[34] Endocarditis involving the aortic 
valve was described in 1937,[30] and more recently in 2015.[23]
Peripheral neuropathies, chorea, meningoencephalitis, cranial 
nerve involvement, headache, malaise, as well as psychiatric 
manifestations, such as depression, anxiety and neurosis, were 
described, indicating nervous system involvement.[33,34,82] Many 
of these psychiatric symptoms were associated with a diagnosis 
of chronic brucellosis with an insidious onset, recorded in 17 SA 
patients.[82] General practitioners referred these patients to specialists 
at the departments of Medicine and Microbiology, University of 
the Free State, Bloemfontein. The patients tested seropositive to 
Brucella, with high titres on repeated serological examination. They 
did not present with fever, but with symptoms listed in Table 1.
Treatment and management
Late initiation of brucellosis treatment is reported to be associated 
with relapse and treatment failure.[67] Currently, the recommended 
treatment regimens for brucellosis patients in SA is described in 
Table 2, and treatment dosages are given in Table 3.
Conclusions and recommendations
Brucellosis caused by B. abortus has been an important medical 
condition for more than a century in SA. Recently, however, there 
has been a paucity of medical literature describing the incidence 
of human brucellosis in SA. Even though there is an active bovine 
brucellosis control programme to prevent human brucellosis in 
the country, persons occupationally exposed to Brucella-infected 
cattle herds are still at risk of brucellosis. The public is also at risk 
through consumption of dairy products contaminated with the 
field or vaccine strain of B. abortus. Evidence of clinical symptoms 
associated with acute, chronic, uncomplicated and focal brucellosis 
in SA is discussed in this article. 
It is recommended that an occupational history, including contact 
with infected cattle herds, be considered by general practitioners 
when diagnosing and treating fever or symptoms of unknown 
origin. Treatment regimens for persons occupationally exposed to 
RB51 should be adjusted to exclude rifampicin. Communication 
between clinicians and veterinarians is recommended to strengthen 
risk-mitigation strategies for individual brucellosis patients as part 
of the management strategy. This has been shown to be integral in 
the formulation of targeted mitigation and risk-reduction strategies 
of public health or government veterinary services.[55,84] Further study 
Table 1. Symptoms and clinical signs in patients (N=17) with 
chronic brucellosis of insidious onset[66]






Muscular pain 11 (64.7)




Agitated pain 2 (11.8)
Clinical sign
Lymphadenopathy 9 (52.9)
Cervical adenopathy 6 (35.3) 
Axillary adenopathy 6 (35.3) 




Joint involvement 1 (5.9)
* Physiological decreased ability of an organism or one of its parts to function because of 
prolonged exertion, which causes toxic decomposition in the muscle and nerve.
† Feeling of weariness but continuing normal activity. The weariness may be physical or 
mental in nature.
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is needed to determine the incidence of Brucella seropositivity in the 
healthy population, especially in bovine brucellosis endemic areas, as 
well as the true burden of human brucellosis in these areas. However, 
routine submission of samples by clinicians suspecting brucellosis 
will help to address the abovementioned information gap. 
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Table 2. Recommended treatment regimens for brucellosis*
Form of brucellosis infection Patients Recommended antibiotic regimen Duration, weeks†
In adults Uncomplicated Doxycycline 6 
Doxycycline plus streptomycin or gentamicin 1 - 2 
or
Doxycycline plus rifampicin 6 
Children, years  
<8 Co-trimoxazole plus rifampicin 4 - 6 
≥8 Doxycycline plus rifampicin
Focal Adults  
Spondylitis Doxycycline 12 
Doxycycline plus streptomycin or gentamicin 2 
or
Doxycycline plus rifampicin 12 
or
Doxycycline plus ciprofloxacin 12 
Neurobrucellosis Doxycycline plus rifampicin plus (ceftriaxone or 
co-trimoxazole)
Prolonged until CSF 
normalises 
Endocarditis Doxycycline plus rifampicin plus streptomycin or 
gentamicin
6 weeks - 6 months, 
depending on clinical 
responseSurgery if indicated
Children, years  
<8 Co-trimoxazole plus streptomycin or 6 (at least)
  gentamicin 2 
≥8 Doxycycline 6 (at least)
  Doxycycline plus streptomycin or gentamicin 2 
  Rifampicin can be added to either regimen 6 (at least)
In pregnancy Rifampicin with/without co-trimoxazole 6 
(avoid in last week before delivery: risk of kernicterus)
Complex focal, relapsed or 
refractory infection, or anti-
biotic toxicity/resistance
Consider adding quinolone or co-trimoxazole as second-
line treatment to doxycycline or rifampicin; triple therapy
has better cure rates
*From Frean et al.,[21] with permission.
†Unless otherwise indicated.
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Ciprofloxacin 1 g/d (2 doses/d)
Ofloxacin 400 mg/d (2 doses/d)
Max. = maximum.
*From Frean et al.,[21] with permission.
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